Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Antimicrob Chemother ; 73(12): 3259-3267, 2018 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-30219855

RESUMEN

Background: Vancomycin-resistant Enterococcus faecium (VREfm) has emerged as a nosocomial pathogen worldwide. The dissemination of VREfm is due to both clonal spread and spread of mobile genetic elements (MGEs) such as transposons. Objectives: We aimed to combine vanB-carrying transposon data with core-genome MLST (cgMLST) typing and epidemiological data to understand the pathways of transmission in nosocomial outbreaks. Methods: Retrospectively, 36 VREfm isolates obtained from 34 patients from seven VREfm outbreak investigations in 2014 were analysed. Isolates were sequenced on a MiSeq and a MinION instrument. De novo assembly was performed in CLC Genomics Workbench and the hybrid assemblies were obtained through Unicycler v0.4.1. Ridom SeqSphere+ was used to extract MLST and cgMLST data. Detailed analysis of each transposon and their integration points was performed using the Artemis Comparison Tool (ACT) and multiple blast analyses. Results: Four different vanB transposons were found among the isolates. cgMLST divided ST80 isolates into three cluster types (CTs); CT16, CT104 and CT106. ST117 isolates were divided into CT24, CT103 and CT105. Within VREfm isolates belonging to CT103, two different vanB transposons were found. In contrast, VREfm isolates belonging to CT104 and CT106 harboured an identical vanB transposon. Conclusions: cgMLST provides a high discriminatory power for the epidemiological analysis of VREfm. However, additional transposon analysis is needed to detect horizontal gene transfer. Combining these two methods allows investigation of both clonal spread as well as the spread of MGEs. This leads to new insights and thereby better understanding of the complex transmission routes in VREfm outbreaks.


Asunto(s)
Brotes de Enfermedades , Enterococcus faecium/genética , Transferencia de Gen Horizontal , Infecciones por Bacterias Grampositivas/transmisión , Secuencias Repetitivas Esparcidas , Enterococos Resistentes a la Vancomicina/genética , Técnicas de Tipificación Bacteriana , Infección Hospitalaria/epidemiología , Infección Hospitalaria/microbiología , Elementos Transponibles de ADN , Enterococcus faecium/clasificación , Enterococcus faecium/efectos de los fármacos , Genoma Bacteriano , Genotipo , Humanos , Tipificación de Secuencias Multilocus , Filogenia , Estudios Retrospectivos , Análisis de Secuencia de ADN
2.
Artículo en Inglés | MEDLINE | ID: mdl-29311068

RESUMEN

Genomic comparison of the first six Dutch vanD-type vancomycin-resistant Enterococcus faecium (VRE) isolates with four vanD gene clusters from other enterococcal species and anaerobic gut commensals revealed that the vanD gene cluster was located on a genomic island of variable size. Phylogenetic inferences revealed that the Dutch VRE isolates were genetically not closely related and that genetic variation of the vanD-containing genomic island was not species specific, suggesting that this island is transferred horizontally between enterococci and anaerobic gut commensals.


Asunto(s)
Enterococcus faecium/efectos de los fármacos , Islas Genómicas/genética , Resistencia a la Vancomicina/genética , Antibacterianos/farmacología , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Enterococcus faecium/genética , Pruebas de Sensibilidad Microbiana , Familia de Multigenes/genética , Filogenia , Vancomicina/farmacología
4.
Eur J Clin Microbiol Infect Dis ; 37(1): 175-183, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29063446

RESUMEN

Health care of severe burn patients is highly specialized and may require international patient transfer. Burn patients have an increased risk of developing infections. Patients that have been hospitalized in countries where carbapenemase-producing microorganisms (CPMO) are endemic may develop infections that are difficult to treat. In addition, there is a risk on outbreaks with CPMOs in burn centers. This study underlines that burn patients may extensively be colonized with CPMOs, and it provides best practice recommendations regarding clinical microbiology and infection control. We evaluated CPMO-carriage and wound colonization in a burn patient initially treated in Romania, and transported to the Netherlands. The sequence types and acquired beta-lactamase genes of highly-resistant microorganisms were derived from next generation sequencing data. Next, we searched literature for reports on CPMOs in burn patients. Five different carbapenemase-producing isolates were cultured: two unrelated OXA-48-producing Klebsiella pneumoniae isolates, OXA-23-producing Acinetobacter baumanii, OXA-48-producing Enterobacter cloacae, and NDM-1-producing Providencia stuartii. Also, multi-drug resistant Pseudomonas aeruginosa isolates were detected. Among the sampling sites, there was high variety in CPMOs. We found 46 reports on CPMOs in burn patients. We listed the epidemiology of CPMOs by country of initial treatment, and summarized recommendations for care of these patients based on these reports and our study.


Asunto(s)
Acinetobacter baumannii/aislamiento & purificación , Antibacterianos/uso terapéutico , Proteínas Bacterianas/metabolismo , Quemaduras/microbiología , Enterobacter cloacae/aislamiento & purificación , Klebsiella pneumoniae/aislamiento & purificación , Providencia/aislamiento & purificación , Pseudomonas aeruginosa/aislamiento & purificación , beta-Lactamasas/metabolismo , Acinetobacter baumannii/efectos de los fármacos , Colistina/uso terapéutico , Desastres , Enterobacter cloacae/efectos de los fármacos , Humanos , Kanamicina/uso terapéutico , Klebsiella pneumoniae/efectos de los fármacos , Linezolid/uso terapéutico , Pruebas de Sensibilidad Microbiana , Países Bajos , Ácido Penicilánico/análogos & derivados , Ácido Penicilánico/uso terapéutico , Piperacilina/uso terapéutico , Combinación Piperacilina y Tazobactam , Providencia/efectos de los fármacos , Pseudomonas aeruginosa/efectos de los fármacos , Rumanía , Sulfadiazina de Plata/uso terapéutico
5.
J Antimicrob Chemother ; 71(5): 1207-12, 2016 May.
Artículo en Inglés | MEDLINE | ID: mdl-26817488

RESUMEN

OBJECTIVES: KPC-2-producing Klebsiella pneumoniae (KPC-KP) ST258 has been rapidly expanding and is often associated with serious nosocomial infections. Last-line antibiotics such as colistin and tigecycline often remain the only treatment option. We describe here the evolving genetic background of KPC-KP isolates in Crete, Greece. METHODS: We tested the antibiotic susceptibility of 34 clinical isolates from patients hospitalized in 2010 and 2013-14. Whole-genome sequences of these isolates were analysed for acquired resistance genes and gene mutations. RESULTS: All KPC-KP isolates belonged to ST258 with the exception of one ST147 isolate. From 2014, 26% of isolates were non-susceptible to all antibiotics, compared with 0 of 11 isolates from 2010. Colistin resistance was associated with mutations in mgrB, which was present in 61% of isolates from 2014. Core-genome MLST analysis showed that pan-resistant isolates were closely related and appeared in two separate clusters. CONCLUSIONS: KPC-KP is rapidly evolving to pan-resistance in Crete. We identified molecular resistance markers for pan-resistant isolates and showed that core-genome MLST is a promising tool for molecular fingerprinting of KPC-KP ST258.


Asunto(s)
Farmacorresistencia Bacteriana Múltiple , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/enzimología , beta-Lactamasas/metabolismo , Genoma Bacteriano , Grecia/epidemiología , Humanos , Klebsiella pneumoniae/aislamiento & purificación , Análisis de Secuencia de ADN
7.
Euro Surveill ; 18(42)2013 Oct 17.
Artículo en Inglés | MEDLINE | ID: mdl-24176580

RESUMEN

We describe the introduction of various multi-drug resistant bacterial strains, including an NDM-1-producing Klebsiella pneumoniae, through a traveller returning from Egypt, where they had been admitted to a private hospital. All family members of the patient were colonised with one or more extended-spectrum beta-lactamase producing strains. These findings emphasise the importance of adherence to isolation precautions for returning patients and suggest the need for inclusion of Enterobacteriaceae in admission screening.


Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana Múltiple , Infecciones por Klebsiella/diagnóstico , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/aislamiento & purificación , Viaje , beta-Lactamasas , Adulto , Egipto , Heces/microbiología , Hospitalización , Humanos , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/genética , Masculino , Países Bajos , Reacción en Cadena de la Polimerasa , Análisis de Secuencia de ADN , Resultado del Tratamiento , Resistencia betalactámica
8.
Clin Vaccine Immunol ; 18(5): 874-7, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21450973

RESUMEN

Tuberculous pericarditis is a rare disease in developed countries. The diagnosis is difficult to set since there are no robust rapid tests, and culture of pericardial fluid for Mycobacterium tuberculosis is often negative. T-SPOT.TB, an enzyme-linked immunospot (ELISPOT) test, measures the gamma interferon response of lymphocytes against tuberculosis antigens and can be performed on blood and body fluids. We describe a patient with tuberculous pericarditis for which the diagnosis was rapidly set by positive T-SPOT.TB results, which were confirmed by isolation of Mycobacterium tuberculosis in pericardial fluid culture. We performed a literature search to assess the diagnostic potential of ELISPOT testing in tuberculous pericarditis. The limited data on this subject indicate that T-SPOT.TB aids in diagnosing active tuberculosis (TB) infection and results in a more rapid decision to start antituberculosis treatment. Enumerating TB-specific lymphocytes and testing blood/compartmental fluid simultaneously can provide useful information on active tuberculous pericarditis.


Asunto(s)
Técnicas de Laboratorio Clínico/métodos , Mycobacterium tuberculosis/inmunología , Pericarditis Tuberculosa/diagnóstico , Ensayo de Immunospot Ligado a Enzimas/métodos , Humanos , Recuento de Linfocitos , Masculino , Mycobacterium tuberculosis/crecimiento & desarrollo , Mycobacterium tuberculosis/aislamiento & purificación , Derrame Pericárdico/microbiología , Adulto Joven
10.
Eur Respir J ; 30(6): 1131-7, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17715164

RESUMEN

In vitro and in vivo studies have shown that carbon monoxide (CO) has both anti-inflammatory and anti-oxidant capacities. Since chronic obstructive pulmonary disease (COPD) is characterised by inflammation and oxidative stress, low-dose CO could be of therapeutic use. The aim of the present study was to investigate the feasibility and anti-inflammatory effects of 100-125 ppm CO inhalation in patients with stable COPD. In total, 20 ex-smoking COPD patients with post-bronchodilator forced expiratory volume in one second (FEV(1)) >1.20 L and FEV(1)/forced vital capacity <70% were enrolled in a randomised, placebo-controlled, crossover study. Effects on inflammation were measured in induced sputum and blood. CO inhalation was feasible and patients' vital signs were unaffected; 2 h.day(-1) inhalation of low-dose CO on 4 consecutive days led to a maximal individual carboxyhaemoglobin level of 4.5%. Two exacerbations occurred in the CO period. CO inhalation led to trends in reduced sputum eosinophils (median reduction 0.25% point) and improved responsiveness to methacholine (median provocative concentration causing a 20% fall in FEV(1) 0.85 versus 0.63 mg.mL(-1)). Inhalation of 100-125 ppm carbon monoxide by patients with chronic obstructive pulmonary disease in a stable phase was feasible and led to trends in reduction of sputum eosinophils and improvement of responsiveness to methacholine. Further studies need to confirm the safety and efficacy in inflammatory lung diseases.


Asunto(s)
Monóxido de Carbono/administración & dosificación , Monóxido de Carbono/uso terapéutico , Inflamación/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Administración por Inhalación , Adulto , Anciano , Anciano de 80 o más Años , Monóxido de Carbono/efectos adversos , Eosinófilos/citología , Femenino , Volumen Espiratorio Forzado , Estado de Salud , Humanos , Pulmón/patología , Masculino , Cloruro de Metacolina/metabolismo , Persona de Mediana Edad , Proyectos Piloto , Esputo/citología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...